lymphoma

According to a company official, the findings indicate the role of polyfunctional T cells in CAR T efficacy and the usefulness of single-cell protein analysis.

A new study suggests that enhanced tumor clone frequencies, found by T cell receptor beta gene sequencing, coincide with poorer mycosis fungoides outcomes.

An exome- and expression-based analysis of 304 DLBCL cases led to five molecular subtypes, offering insights into disease pathogenesis and treatment outcomes.

The group now plans to run the 32-gene panel in clinical trials to demonstrate its utility and make the case for offering it within Canada's healthcare system.

The two companies are entering a partnership to introduce diagnostic tests using NanoString's nCounter technology in Japan, beginning with a lymphoma assay.

A GWAS and meta-analysis linked Hodgkin lymphoma risk to variants in sequences related to B cell development, immune function, and autoimmune disease risk.

The companion diagnostic will leverage ArcherDx's Anchored Multiplex PCR technology, Illumina's MiSdqDx sequencer, and Archer Analysis bioinformatics software. 

Second One From Kite

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

The company said it plans to use the proceeds raised in the private placement primarily to fund its Hodgkin's lymphoma test clinical trial.

This Week in Science

In Science this week: two proteins may help treat muscular dystrophy, and more.

Pages

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.